Akoya Biosciences, Inc. SEC Filings

Welcome to our dedicated page for Akoya Biosciences SEC filings (Ticker: AKYA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

The SEC filings page for Akoya Biosciences, Inc. (AKYA) provides access to the company’s historical regulatory documents, including reports that detail its operations as a public company and the corporate actions that led to its acquisition by Quanterix Corporation. These filings cover financial statements, risk disclosures, and material events related to Akoya’s role as The Spatial Biology Company®, offering single-cell imaging and spatial proteomics solutions for discovery, translational, and clinical research.

Investors can review periodic reports such as Forms 10-K and 10-Q (where available) to understand how Akoya described its revenue composition between product and service activities, its installed base of instruments, and the growth in publications citing its technology. These documents also typically include discussions of research collaborations, market focus in spatial biology and immuno-oncology, and factors affecting operations and funding.

Material event filings on Form 8-K are especially important for understanding Akoya’s corporate trajectory. A Form 8-K filed on July 8, 2025 explains that Akoya completed the transactions under the Amended and Restated Agreement and Plan of Merger with Quanterix, with Wellfleet Merger Sub, Inc. merging into Akoya and Akoya surviving as a wholly owned subsidiary of Quanterix. The filing outlines the merger consideration structure, the treatment of equity awards, the repayment and termination of Akoya’s credit agreement, and changes in control, governance, and key corporate agreements.

For trading status, a Form 25 filed on July 8, 2025 by the Nasdaq Stock Market LLC notifies the SEC of the removal of Akoya’s common stock from listing and registration on the Nasdaq Global Select Market. Akoya’s Form 8-K further notes its intention to file a Form 15 to terminate the registration of its common stock and suspend reporting obligations under the Exchange Act. Together, these filings document the transition of AKYA from a Nasdaq-listed security to the equity of a wholly owned subsidiary within Quanterix.

On this page, AI-powered tools can help users interpret complex filings by summarizing key points from lengthy documents such as merger agreements, 10-Ks, and 10-Qs. These summaries can highlight items like revenue breakdowns, major collaborations, capital structure changes, and the specific terms and implications of the Quanterix merger, aiding investors and researchers who are examining AKYA’s historical regulatory record.